Madrigal's Rezdiffra Soars, Pipeline Expands

Madrigal Pharmaceuticals star drug Rezdiffra for MASH liver disease is on fire, with Q1 2026 net sales surging 127% to $311M, and over $1.1B in sales in the past year. The addressable patient pool in the U.S. has nearly doubled since launch, with penetration under 10%. Prescribers and patients love it, with strong real-world data and high adherence rates. Madrigal is expanding its pipeline with ARO-PNPLA3, showing promising results in Phase 1 trials. The company is well-funded, with a cash pile of $818M, and is poised to lead the MASH market with its long-term strategy. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c7377859664814a3